Phase I / II study for appropriate dose of Erlotinib in patients with lung adenocarcinoma having the sensitive mutation to epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI).
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2018
At a glance
- Drugs Erlotinib (Primary)
- Indications Lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 May 2018 Status changed from recruiting to completed.
- 23 Nov 2013 Status changed from suspended to recruiting as reported by University Hospital Medical Information Network - Japan.
- 25 Aug 2013 Status changed from recruiting to suspended as reported by University Hospital Medical Information Network - Japan.